

Description:	This purified rabbit monoclonal antibody recognizes recombinant wildtype SARS-CoV-2 Spike RBD and trimeric spike proteins. Additionally, this antibody cross-reacts with the Delta variant (B.1.617.2) Spike S1 and trimeric proteins and with the Delta Plus variant (B.1.617.2.1) trimer. This antibody also cross reacts with variant Alpha (B.1.1.7; U.K.), Beta (B.1.351; South African), and Gamma (P.1; Brazilian) Spike RBD and trimeric proteins. This neutralizing antibody impedes the interaction between SARS-CoV-2 Spike and human ACE2 receptor. ACE2 receptor is known to mediate COVID-19 infection through direct binding of the SARS-CoV2 Spike protein. This neutralizing antibody has been functionally tested using BPS Bioscience Spike RBD: ACE2 Inhibitor Screening Kits and using Spike pseudotyped lentiviruses in cell-based assays.
Concentration:	0.5 mg/ml
Species:	Rabbit
Clone:	C-A11
Isoform:	IgG
Immunogen:	SARS-CoV-2 Spike RBD
Formulated In:	PBS
Purification:	Protein A affinity chromatography
Format:	Aqueous buffer solution
Storage:	4°C
MW:	150 kDa
Assay Conditions:	<p><i>Experimental design and assay protocol for measuring the neutralizing activity of the antibody using Spike Trimer (S1+S2) (B.1.1.7 Variant) (SARS-CoV-2): ACE2 Inhibitor Screening Colorimetric Assay Kit, #AMS.78175</i></p> <ol style="list-style-type: none">1. Coat a flat bottom clear 96-well plate with 1 µg/ml spike protein diluted in PBS overnight at 4°C.2. The next day, dilute one volume of 3x Immuno Buffer 1 (#AMS.79311) with 2volumes of distilled water to bring it to 1x Immuno Buffer1. Wash threetimes with 100 ul of 1x Immuno Buffer 1. Then, block with100 ul of Blocking Buffer 2 (#AMS.79728) for 1 hour at room temperature with gentleshaking.3. Wash with 1x Immuno Buffer 1 and add serial dilutions of neutralizing antibody (suggested initial range: 100 nM to pM range) to the plate containing the coated spike protein, for 30 minutes at room temperature with gentle shaking.4. Without removing the antibody, add 100 ul of ACE2-biotin (#AMS.100665) diluted in Blocking Buffer 2 at a final concentrationof 1.5ng/ul. Incubate for 1 hour at room temperature with gentle shaking.5. Wash three times with 1x Immuno Buffer 1 and add HRP-Streptavidin diluted in Blocking Buffer 2.6. Wash three times with 1x Immuno Buffer 1 and add 100 µl of Colorimetric HRP substrate. Quench the reaction with 100 µl of 1N HCL after color development.6. Read absorbance at 450 nm.

AMSBIO | www.amsbio.com | info@amsbio.com



UK & Rest of the World
184 Park Drive, Milton Park
Abingdon OX14 4SE, U.K.
T: +44 (0) 1235 828 200
F: +44 (0) 1235 820 482



North America
1035 Cambridge Street,
Cambridge, MA 02141.
T: +1 (617) 945-5033 or
T: +1 (800) 987-0985
F: +1 (617) 945-8218



Germany
Bockenheimer Landstr. 17/19
60325 Frankfurt/Main
T: +49 (0) 69 779099
F: +49 (0) 69 13376880



Switzerland
Via Lisano 3
(CP.683)
6900 Massagno
T: +41 (0) 91 604 55 22
F: +41 (0) 91 605 17 85

Figure 1A.




Figure 1B.




Figure 1C.

SARS-CoV-2 Trimers:ACE2 neutralizing C-A11 Assay




Figure 1D.

SARS-CoV-2 RBD Proteins: Ace2 C-A11 Neutralizing Assay




Figure 1. Neutralization of the interaction between spike protein variants and human ACE2

Clone C-A11 Neutralizing antibody competes with and blocks the binding of ACE2-biotin to immobilized recombinant SARS-CoV-2 Spike proteins (1 µg/ml) following the assay conditions described above. This neutralizing activity was empirically tested in a colorimetric ELISA assay with the following target SARS-CoV-2 variant proteins:

A) India Delta B.1.617.2 Trimer (#AMS.101147) and India Delta Plus B.1.617.2.1 Trimer (#AMS.101165)

B) Emerging India Delta B.1.617.2 Spike S1 Protein (#AMS.101151)

C) Spike trimers wild-type (#AMS.100728), B.1.351 (#AMS.510333), P.1 (#AMS.100989), B.1.351Δ242-244 (#AMS.101091), and B.1.1.7 (#AMS.510334)

D) Wild-type spike RBD (#AMS.100696), B.1.1.7 RBD (#AMS.100977), B.1.351 RBD (#AMS.100978), and P.1 RBD (#AMS.100993)

*This data is representative, please inquire for lot-specific information

Figure 2




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 2E

Figure 2: Cell-based neutralization assay using anti-SARS-CoV-2 Spike antibody (clone# C-A11)

Approximately 8,000 ACE2-HEK293 cells/well were transduced with 10 μ l/well of Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter)/anti-Spike antibody mix. After 48 hours of transduction, ONE-Step Luciferase reagent (#AMS.60690) was added to the cells to measure the luciferase activity, indicative of the transduction efficiency. The transduction efficiency measured in the wells containing only the pseudovirus (no antibody treatment) was set as 100%, while the transduction efficiency measured in the wells without virus was set as 0%.

A. Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter) (#AMS.79942);

B. Spike (B.1.1.7 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter) (#AMS.78112);

C. Spike (B.1.351 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter) (#AMS.78142);

D. Spike (P.1 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter) (#AMS.78144);

E. Spike (B.1.429 Variant) (SARS-CoV-2) Pseudotyped Lentivirus (Luc reporter) (#AMS.78172)